Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Open Access
- 13 April 2023
- journal article
- review article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 16 (1) , 1-37
Abstract
The advent of immunotherapy has made an indelible mark on the field of cancer therapy, especially the application of immune checkpoint inhibitors in clinical practice. Although immunotherapy has proven its efficacy and safety in some tumors, many patients still have innate or acquired resistance to immunotherapy. The emergence of this phenomenon is closely related to the highly heterogeneous immune microenvironment formed by tumor cells after undergoing cancer immunoediting. The process of cancer immunoediting refers to the cooperative interaction between tumor cells and the immune system that involves three phases: elimination, equilibrium, and escape. During these phases, conflicting interactions between the immune system and tumor cells result in the formation of a complex immune microenvironment, which contributes to the acquisition of different levels of immunotherapy resistance in tumor cells. In this review, we summarize the characteristics of different phases of cancer immunoediting and the corresponding therapeutic tools, and we propose normalized therapeutic strategies based on immunophenotyping. The process of cancer immunoediting is retrograded through targeted interventions in different phases of cancer immunoediting, making immunotherapy in the context of precision therapy the most promising therapy to cure cancer.Keywords
Funding Information
- National Key R&D Program of China (2018YFC1313400)
- Tianjin Natural Science Foundation (19JCYBJC27600 and 18JCQNJC81300, 19JCYBJC27600 and 18JCQNJC81300)
- National Natural Science Foundation of China (U20A20375, 81974416, 81872166 and 81802873, U20A20375, 81974416, 81872166 and 81802873)
This publication has 403 references indexed in Scilit:
- Arthritis augments breast cancer metastasis: role of mast cells and SCF/c-Kit signalingBreast Cancer Research, 2013
- Chemoimmunotherapy: reengineering tumor immunityCancer Immunology, Immunotherapy, 2013
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1Nature Immunology, 2012
- The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinomaBritish Journal of Cancer, 2011
- The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapyCell Death & Differentiation, 2011
- Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor ProgressionCancer Cell, 2011
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous MalignancyImmunity, 2008
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002